Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.10 USD
Change Today 0.00 / 0.00%
Volume 0.0
PRNAF On Other Exchanges
Symbol
Exchange
Berlin
OTC US
Stuttgart
As of 8:10 PM 04/16/15 All times are local (Market data is delayed by at least 15 minutes).

prana biotechnology ltd (PRNAF) Key Developments

Prana Biotechnology Limited Reports Consolidated Cash Flow Results for the Third Quarter and Nine Months Ended March 31, 2015

Prana Biotechnology Limited reported consolidated cash flow results for the third quarter and nine months ended March 31, 2015. For the quarter, the company reported net operating cash flows (carried forward) of AUD 4,360,000 and payment for acquisition of physical non-current assets of AUD 4,000. For the nine months, the company reported net operating cash flows (carried forward) of AUD 12,783,000 and payment for acquisition of physical non-current assets of AUD 26,000.

Prana Biotechnology Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

Prana Biotechnology Limited reported consolidated earnings results for the half year ended December 31, 2014. For the period, the company reported loss after income tax of AUD 1,252,695 compared to AUD 7,928,392 for the same period a year ago. Revenue from ordinary activities was AUD 92,581 compared to AUD 189,588 a year ago. Loss before income tax expense was AUD 1,252,695 compared to AUD 7,928,392 a year ago. Basic and diluted loss per share was 0.26 cents compared to 1.97 cents a year ago. Net operating cash flows were AUD 8,411,407 compared to AUD 7,435,475 a year ago. Payment for purchases of plant and equipment was AUD 24,942 compared to AUD 12,718 a year ago. The loss has decreased compared to previous year due to a gain on foreign exchange, an increase in other income related to the R&D Tax Concession and a decrease in expenditure on research and development.

Prana Biotechnology Limited(ASX:PBT) dropped from S&P/ASX 300 Index

Prana Biotechnology Limited(ASX:PBT) dropped from S&P/ASX 300 Index

Prana Biotechnology Limited(ASX:PBT) dropped from S&P/ASX Small Ordinaries Index

Prana Biotechnology Limited(ASX:PBT) dropped from S&P/ASX Small Ordinaries Index

Prana Biotechnology Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

Prana Biotechnology Limited reported consolidated earnings results for the half year ended December 31, 2014. For the period, the company reported loss after income tax of AUD 1,252,695 compared to AUD 7,928,392 for the same period a year ago. Revenue from ordinary activities was AUD 92,581 compared to AUD 189,588 a year ago. Loss before income tax expense was AUD 1,252,695 compared to AUD 7,928,392 a year ago. Basic and diluted loss per share was 0.26 cents compared to 1.97 cents a year ago. Net operating cash flows were AUD 8,411,407 compared to AUD 7,435,475 a year ago. Payment for purchases of plant and equipment was AUD 24,942 compared to AUD 12,718 a year ago. The loss has decreased compared to previous year due to a gain on foreign exchange, an increase in other income related to the R&D Tax Concession and a decrease in expenditure on research and development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRNAF:US $0.10 USD 0.00

PRNAF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRNAF.
View Industry Companies
 

Industry Analysis

PRNAF

Industry Average

Valuation PRNAF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.7x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRANA BIOTECHNOLOGY LTD, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.